Non-Steroidal Anti-Inflammatory Drugs in Food Producing Animals

De Vito Virginia

Department of Veterinary Medicine, University of Sassari, Via Vienna 2, 07100 Sassari, Italy

Abstract: Providing adequate food supply to meet the demands of a growing population is a challenge for this century. The food producing animals bred in optimized conditions supply a large amount of food derivatives. At the same time, society has become progressively more concerned about animal suffering and aware of the need of pain prevention and treatments. One of the measures aimed at improving animals welfare is pain management a rational and controlled use of the anti-inflammatory drugs such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). However, NSAIDs residues in biological matrices are still an issue. In addition veterinary pharmacology still has a reduced drug armamentarium if compared with human medicine. In order to address these shortfalls investigations on new NSAIDs (off label drug) in food producing animals are needed.

Keywords: Pain Management, Food Producing Animals, Non-Steroidal Anti-Inflammatory Drugs, Off Label Drugs, Residues

Introduction

Over the last decades, animal production science supported the modernization of food animal husbandry in order to provide adequate food supply to meet the demands of a growing population. The food producing animals bred in optimized conditions supply a large amount of food derivatives (milk, eggs, meat, honey and fish) and produce foodstuffs that are safe for the human consumption.

Furthermore, in the recent years, society has become progressively more concerned about food producing animals suffering and aware of the need of pain prevention and treatments due to the routine husbandry procedures such as castration and dehorning (Bomzon, 2011).

‘Freedom from pain, injury and disease’ for breeding animals was early recognised by the Farm Animal Welfare Advisory Committee in 1967 as one of the five minimal requirements to guarantee animal welfare, known as the ‘Five Freedoms’ (Brambell, 1965).

‘Freedom from pain, injury and disease’ for breeding animals was early recognised by the Farm Animal Welfare Advisory Committee in 1967 as one of the five minimal requirements to guarantee animal welfare, known as the ‘Five Freedoms’ (Brambell, 1965).

Animal welfare has recently made the headlines of the popular media: mishandling of cows, new laws that ban the use of sow gestation crates and chicken battery cages and hidden cameras at intensive breeding farm are only few examples (Fajt et al., 2011).

Pain is a sensory process that results from tissue damage and is intended to prevent further tissue damage following injury. Pain activates numerous physiological reactions that often induce negative effects on well-being and behaviour, as well as on growth and reproduction of the animals. However, the main obstacle for the pain management in farm animals is to recognise, quantify and evaluate the pain status of each individual in a farm or to treat pain in a single individual without disturbing the whole group of animals (Guatteo et al., 2012).

In veterinary medicine, recently, pain has been shown to affect animal welfare and production and the interest in the field of analgesia has been drastically increasing (Lee et al., 2014). Therefore, the desirable medication associated with the pain status of each individual will be important to treat pain in farm animals.

A similar specific approach designed to minimize pain in laboratory animals is also required in farm animals. Nowadays, the concepts of “Replacement, Reduction and Refinement”, called the ‘3Rs’ (Russell and Burch, 1959), used in the design of animals experiments to minimise unnecessary pain, is the basis of a new approach the ‘3S’ ‘Suppress, Substitute and Soothe pain. This approach is used to review existing practical solutions and find new solutions to eliminate or alleviate pain in farm animals. It is based on the possibility to “suppress” the procedures or environments that are a source of pain, to “substitute” such procedures by others causing less pain and to “soothe” pain when it cannot be avoided (Guatteo et al., 2012).
Table 1. Maximum Residue Limits (MRLs) for the most used veterinary NSAIDs and COX-2 inhibitor

| Pharmacologically active substance | Animal species | MRLs (µg/kg) | Target tissue |
|-----------------------------------|----------------|--------------|---------------|
| Carprofen                         | Bovine         | 500          | Muscle        |
|                                   | Equine         | 500          | Muscle        |
|                                   | Bovine         | 1000         | Liver         |
|                                   | Equine         | 1000         | Liver         |
| Flunixin                          | Bovine         | 300          | Liver         |
|                                   | Porcine        | 100          | Liver         |
|                                   | Equine         | 200          | Liver         |
|                                   | Bovine         | 100          | Kidney        |
|                                   | Bovine         | 30           | Fat           |
|                                   | Bovine         | 20           | Muscle        |
|                                   | Porcine        | 50           | Muscle        |
|                                   | Equine         | 10           | Muscle        |
| 5-Hydroxyflunixin                 | Bovine         | 40           | Milk          |
| Flunixin                          | Porcine        | 200          | Liver         |
|                                   | Porcine        | 50           | Muscle        |
|                                   | Porcine        | 30           | Kidney        |
|                                   | Porcine        | 10           | Skin+Fat      |
| Meloxicam                         | Bovine         | 65           | Liver         |
|                                   | Porcine        | 65           | Liver         |
|                                   | Equine         | 65           | Liver         |
|                                   | Bovine         | 65           | Kidney        |
|                                   | Bovine         | 20           | Muscle        |
|                                   | Porcine        | 20           | Muscle        |
|                                   | Equine         | 20           | Muscle        |
|                                   | Bovine         | 15           | Milk          |
|                                   | Porcine        | 20           | Muscle        |
|                                   | Equine         | 20           | Muscle        |
| Tolfenamic acid                   | Bovine         | 400          | Liver         |
|                                   | Bovine         | 50           | Muscle        |
|                                   | Porcine        | 400          | Liver         |
|                                   | Porcine        | 50           | Muscle        |
| Diclofenac                        | Bovine         | 5            | Muscle        |
|                                   | Porcine        | 5            | Muscle        |
| Ketoprofen                        | No MRL required|             |               |
| Mefenamic acid                    | Bovine         | 10           | Muscle        |
|                                   | Porcine        | 10           | Muscle        |
|                                   | Equine         | 10           | Muscle        |
|                                   | Chicken        | 10           | Muscle        |
| Naproxen                          | Bovine         | 10           | Muscle        |
|                                   | Porcine        | 10           | Muscle        |
|                                   | Equine         | 10           | Muscle        |
|                                   | Chicken        | 10           | Muscle        |
| Oxyphenbutazone                   | Bovine         | 5            | Muscle        |
|                                   | Porcine        | 5            | Muscle        |
|                                   | Equine         | 5            | Muscle        |
|                                   | Chicken        | 5            | Muscle        |
| Phenylbutazone                    | Bovine         | 5            | Muscle        |
|                                   | Porcine        | 5            | Muscle        |
|                                   | Equine         | 5            | Muscle        |
|                                   | Chicken        | 5            | Muscle        |
| Firocoxib                         | Equine         | 60           | Liver         |
|                                   | Equine         | 10           | Kidney        |
|                                   | Equine         | 15           | Fat           |
|                                   | Equine         | 10           | Muscle        |
Animal welfare issues in food production are now being driven by animal activists, food companies and consumers. Consequently, animal welfare assurance programs have been developed and are encoded in non-mandatory codes or guidelines, government regulations, inter-governmental agreements and corporate programs (Fraser, 2006).

One of the measures aimed at improving animals welfare is pain management by using anti-inflammatory drugs. These substances can be effective in suppressing or preventing inflammation, treating allergy, lowering fever and reducing pain.

The classes of anti-inflammatory drugs differ on the basis of their actions towards the biochemical mediators that are released during inflammation and that propagate the inflammatory response. One of the main classes of anti-inflammatory drugs most used in veterinary medicine for food producing animals is the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Gentili, 2007; Malone et al., 2009).

The NSAIDs are widely used because of their ability to reduce inflammatory process. NSAIDs can be classified into several groups according to their chemical structure: The propionic acid derivatives (Ketoprofen, Carprofen, Vedaprofen, Naproxen); the anthranilic acid derivatives (Tolfenamic acid, Mefenamic acid); the nicotinic acid derivatives (Flunixin); the pyrazolones (Phenylbutazone) and the acetic acid derivatives (Diclofenac); the class of oxicams (Meloxicam) (Dubreil-Chéneau et al., 2011).

In veterinary practice NSAIDs are used in the treatment of musculoskeletal disorders, coliform mastitis, pulmonary diseases and enteritis in several animal species. NSAIDs, however, because of their toxicity, can affect the gastro-intestinal, hematopoietic and renal systems. Gastro-intestinal ulcerations are the most common and serious side effect of NSAIDs, especially in cases of overdose or chronic abuse. In the last decade a new sub class of NSAID named Cyclooxygenase-2 selective inhibitor (COX-2), has been developed and introduced in veterinary medicine. A benefit of this class is that it seems to lower the adverse effects triggered by the classical NSAID drugs. On the other side the COX-2 inhibitor drug pharmacokinetic and pharmacodynamic profiles can change from species to species (Kim et al., 2014a; 2014b) and very few data in food producing animal species are available so far. Another concern is their cost that so far is much higher than that of classical NSAID.

A wide number of classical NSAIDs are authorized for food producing animals. The widespread use of these drugs presents the potential risk for the consumers if food containing residues enters the food chain. For this reason there is a need for the control of residues and development of methods to monitor their compliance with legislation (Jedziniak et al., 2010). In order to protect consumer health, the European Union has set Maximum Residue Limits (MRLs) for these substances. The MRLs range from 10 to 1000 µg kg\(^{-1}\), depending on the compound and matrix (Igualada et al., 2007). Table 1 show the MRLs for NSAIDs in food producing animals in different matrices (Jedziniak et al., 2010; Gentili, 2007; Dubreil-Chéneau et al., 2011; Igualada et al., 2007). Differently, only firocoxib in the COX-2 selective inhibitor class is authorized in the European Union in a single farm animal species (horse) with a MRLs range from 10 to 60 µg kg\(^{-1}\), depending on the matrix (Woodward, 2012; EMEA, 2006).

| Methods          | Matrices     | References                                |
|------------------|--------------|-------------------------------------------|
| LC-MS/MS         | Milk         | Daeseleire et al., (2003); Gallo et al., (2008); Penney et al., (2005); Boner et al., (2003a) |
|                  | Liver        | Boner et al., (2003b); Croubels et al., (2004) |
|                  | Fat          | Boner et al., (2003b)                     |
|                  | Muscle       | Boner et al., (2003b); Chrusch et al., (2008); Penney et al., (2005); Van Hooft et al., (2004) |
|                  | Kidney       | Boner et al., (2003b); Chrusch et al., (2008); Clark et al., (2002); Croubels et al., (2004) |
|                  | Plasma       | Croubels et al., (2004); Vinci et al., (2006) |
|                  | Excreta      | Croubels et al., (2004)                   |
| LC/ESI-MS/MS     | Milk         | Gallo et al., (2008)                      |
|                  | Plasma       | Vinci et al., (2006)                      |
|                  | Liver        | Igualada et al., (2007)                   |
|                  | Muscle       | Igualada et al., (2007)                   |
| UPLC-ToF-MS      | Milk         | Stolker et al., (2008)                    |
| RRLC-MS/MS       | Milk         | Dowling et al., (2009)                    |
| GC-MS            | Liver        | Hines et al., (2004); Takeda et al., (2001) |
|                  | Milk         | Stolker et al., (2008); Dowling et al., (2008) |
| HPLC-UV          | Plasma       | Cartula and Cusido, (1992); De Veaau et al., (1998); Ian De Veaau, (1999); Jedziniak et al., (2007); Fiori et al., (2004) |
|                  | Milk         | De Veaau, (1996); De Veaau et al., (1998) |
|                  | Liver        | Hines et al., (2004)                      |
| HPLC-FL          | Liver        | Hines et al., (2004)                      |
Different methods for the determination of NSAIDs in biological matrices and concerning residues of these drugs in food of animal origins are widely described in the literature (Table 2). Multitude of analyses and low limits of NSAIDs residues in biological matrices make LC-MS/MS the preferable technique for both screening and confirmatory purposes. Moreover, the development of multi-residue procedure for drugs differing in chemical properties is the main challenge in determination of NSAIDs residues (Jedziniak et al., 2010).

The steadily emerging concept of pain management in veterinary medicine has resulted in increased interest in the development of new techniques for pain management (De Vito et al., 2014). However, veterinary pharmacology still has a limited drug armamentarium. It is pivotal that new human drugs and therapies be tested also in veterinary species (Lee et al., 2014). Furthermore in farm animals, veterinarians are commonly faced with the need to administer drugs to a species that is not in accordance with label directions. When using pharmaceuticals in an extralabel fashion, the veterinarian assumes the legal responsibility of assuring that the product is safe, efficacious and will not leave harmful residues in animal products intended for human consumption. The Animal Medicinal Drug and Cosmetics Act allows veterinarians to prescribe approved animal drugs in an extralabel fashion but also defined several conditions and stipulations including:

- Extralabel use of an approved human drug is not permitted in food producing animals if an approved animal drug can be use in extralabel fashion
- Extralabel drug use is permitted only by the order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship
- No other approved animal drug is labelled and contains the same active ingredient in the required dosage and concentration, except when the veterinarian finds the approved drug to be clinically ineffective
- The health of the animals is threatened, or suffering or death may result from failure to treat
- Extralabel drug use is not permitted to enhance production or feed additives
- Assure that the identity of the treated animal is recorded and records are maintained
- Appropriate labelling information including withdrawal times for meat, milk and eggs as specified by the veterinarian must be provided
- Extralabel use that may result in residues above an established safe level or tolerance or present a risk to public health is not permitted (Lin and Walz., 2014; Bates et al., 2014)

**Conclusion**

In conclusion, classical NSAIDs are considered drugs of high regulatory concern in food producing animals because of the potential for harm to humans consuming food and food by-products containing residues. It is important hence for veterinarians dealing with food producing animal to be familiar with drugs useful to reduce pain. At the same time they have to be aware of the regulations governing the use of approved and extralabel drugs in practice, respecting the right and different MRLs and withdrawal time to produce foodstuffs that are safe for the human consumption (Smith et al., 2008).

**References**

Bates, J.L., L.A. Karriker, M.L. Stock, K.M. Pertzborn and L.G. Baldwin et al., 2014. Impact of transmammary-delivered meloxicam on biomarkers of pain and distress in piglets after castration and tail docking. PLOS ONE, 9: e113678. DOI: 10.1371/journal.pone.0113678

Bomzon, A., 2011. Pain and stress in cattle: A personal perspective. Isr. J. Vet. Med., 66: 1-58.

Boner, P.L., D.D. Liu, W.F. Feely, M.J. Wisocky and J. Wu, 2003a. Determination and confirmation of 5-hydroxyflunixin in raw bovine milk using liquid chromatography tandem mass spectrometry. J. Agric. Food Chem., 51: 3753-3759. DOI: 10.1021/jf034288

Boner, P.L., D.D. Liu, W.F. Feely, R.A. Robinson and J. Wu, 2003b. Determination of flunixin in edible bovine tissues using liquid chromatography coupled with tandem mass spectrometry. J. Agric. Food Chem., 51: 7555-7559. DOI: 10.1021/jf034880n

Brambell, F.W.R., 1965. Report of the technical committee to enquire into the welfare of animals kept under intensive livestock husbandry systems. H.M. Stationery Office Cmmand 2836, London.

Cartula, M.C. and E. Cusido, 1992. Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds. J. Chromatogr B: Biomed. Sci. Appli., 581: 101-107. DOI: 10.1016/0378-4347(92)80452-V

Chrusch, J., S. Lee, R. Fedeniuk and J.O. Boison, 2008. Determination of the performance characteristics of a new multi-residue method for non-steroidal anti-inflammatory drugs, corticosteroids and anabolic steroids in food animal tissues. Food Addit. Contam. Part A, 25: 1482-1496. DOI: 10.1080/02652030802273122
Clark, S.B., S.B. Turnipseed, G.J. Nandrea, M.R. Madson and J.A. Hurlbut et al., 2002. Confirmation of phenylbutazone residues in bovine kidney by liquid chromatography/mass spectrometry. J. AOAC Int., 85: 1009-1014.

Croubels, S., A. Maes, K. Baert and P. De Baker, 2004. Quantitative determination of salicylate and metabolites in animal tissues by LC-MS/MS. Proceedings of the Euroresidue Conference Residues of Veterinary Drugs in Food, Noorderwijkhout (DFN’ 04), The Netherlands, Ghent University Academic Bibliography, pp: 416-421.

Daeseleire, E., L. Mortier De, H. Ruyck and N. Geerts, 2004. Determination of flunixin and ketoprofen in milk by liquid chromatography-tandem mass spectrometry. Food Additives Contaminants: Part A, 21: 437-443.

De Vito, V., B. Łebkowska-Wieruszewska, H. Owen, C.J. Kowalski and M. Giorgi, 2014. Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. J. Vet. Pharmacol. Ther., 21: 437-443. DOI: 10.1046/j.1365-2885.1998.00167.x

De Vito, V., B. Lebkowska-Wieruszewska, H. Owen, C.J. Kowalski and M. Giorgi, 2014. Pharmacokinetic profiles of the analgesic drug flupirtine in cats. Vet. J., 202: 309-313. DOI: 10.1016/j.tvjl.2014.06.011

Dowling, G., P. Gallo, E. Malone and L. Regan, 2009. Rapid confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by rapid resolution liquid chromatography tandem mass spectrometry. J. Chromatogr. A, 1216: 8117-1831. PMID: 18823913

Dowling, G., P. Gallo, S. Fabbrocino, L. Serpe and L. Regan, 2008. Determination of ibuprofen, ketoprofen, diclofenac and phenylbutazone in bovine milk by gas chromatography-tandem mass spectrometry. Food Additives Contaminants: Part A, 25: 1497-508. DOI: 10.1080/02652030802383160

Dubreil-Chéneau, E., Y. Pirotais, M. Bessiral, B. Roudaut and E. Verdon, 2011. Development and validation of a confirmatory method for the determination of 12 non steroidal anti-inflammatory drugs in milk using liquid chromatography-tandem mass spectrometry. J. Chromatogr. A, 1218: 6292-6301. DOI: 10.1016/j.chroma.2011.06.006

EMEA, 2006. EMEA/CVMP/383063/2006-Final. Analgesic drug administration and attitudes about analgesia in cattle among bovine practitioners in the United States. J. Am. Vet. Med. A., 238: 755-767. DOI: 10.2460/javma.238.6.755

Fiori, M., M. Farne’, C. Civitareale, A. Nasi and L. Serpe et al., 2004. The Use of bovine serum albumin as a ligand in affinity chromatographic clean-up of non-steroidal anti-inflammatory drugs from bovine plasma. Chromatographia, 60: 253-257. DOI: 10.1365/s10337-004-0370-1

Fraser, D., 2006. Animal welfare assurance programs in food production: A framework for assessing the options. Anim. Welf., 15: 93-104.

Gallo, P., S. Fabbrocino, F. Vinci, M. Fiori and V. Danese et al., 2008. Confirmatory identification of sixteen nonsteroidal anti-inflammatory drug residues in raw milk by liquid chromatography coupled with ion trap mass spectrometry. Rapid Commun. Mass Spectrom., 22: 841-854. DOI: 10.1002/rcm.3430

Gentili, A., 2007. LC-MS methods for analyzing anti-inflammatory drugs in animal-food products. Trends Anal. Chem., 26: 595-608. DOI: 10.1016/j.trac.2007.01.013

Guatteo, R., O. Levionnois, D. Fournier, D. Gue’mene and K. Latouche et al., 2012. Minimising pain in farm animals: the 3S approach—‘Suppress, Substitute, Soothe’. Animal, 6: 1261-1274. DOI: 10.1017/S1751731112000262

Hines, S., J. Bright and C. Pearce, 2004. Screening and confirmatory residue analysis of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in bovine, porcine and equine liver by high performance liquid chromatography-fluorescence/UV (HPLC-fluorescence and HPLC-UV) and Gas Chromatography-Mass Spectrometry (GC-MS). Proceedings of the EuroResidue V-Conference on Residues of Veterinary Drugs in Foods. Noordwijkerhout, the Netherlands, pp: 520-26.

Ia De Veau, E.J., 1999. Determination of non-protein bound phenylbutazone in bovine plasma using ultra filtration and liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 721: 141-145. DOI: 10.1016/S0378-4347(98)00487-3

Igualada, C., F. Moragues and J. Pitarch, 2007. Rapid method for the determination of non-steroidal anti-inflammatory drugs in animal tissue by liquid chromatography-mass spectrometry with ion-trap detector. Anal. Chim. Acta, 586: 432-439. DOI: 10.1016/j.aca.2006.10.040

Jedziniak, P., T. Szprengier-Juszkiewicz, M. Olejnik and J. Jaroszewski, 2007. Determination of flunixin and 5-hydroxylflunixin in bovine plasma with HPLC-UV method development, validation and verification. Bull. Inst. Vet. Pulawy, 51: 261-266.

Jedziniak, P., T. Szprengier-Juszkiewicz, M. Olejnik and J. Zmudzki, 2010. Determination of non-steroidal anti-inflammatory drugs residues in animal muscles by liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta, 672: 85-92. DOI: 10.1016/j.aca.2010.04.031
Kim, T.W., G. Della Rocca, A. Di Salvo, R. Ryschanova and M. Sgorbini et al., 2014a. Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. New Zeal. Vet. J. DOI: 10.1080/00480169.2014.950355

Kim, T.W., G. Della Rocca, A. Di Salvo, H. Owen and M. Sgorbini et al., 2014b. Pharmacokinetics of the novel cyclooxygenase 2 Inhibitor cimicoxib in donkeys. J. Equine. Vet. Sci., 34: 923-925. DOI: 10.1016/j.jevs.2014.02.004

Lee, H.K., V. De Vito and M. Giorgi, 2014. Soluble epoxide hydrolase inhibitors: New molecules with potential for use in veterinary medicine. Isr. J. Vet. Med., 69: 1-7.

Lin, H.C. and P. Walz, 2014. Farm Animal Anesthesia: Cattle, Small Ruminants, Camelids and Pigs. Wiley, ISBN-10: 1118474368, pp: 352.

Malone, E.M., G. Dowling, C.T. Elliott, D.G. Kennedy and L. Regana, 2009. Development of a rapid, multi-class method for the confirmatory analysis of anti-inflammatory drugs in bovine milk using liquid chromatography tandem mass spectrometry. J. Chromatogr. A, 1216: 8132-8140. DOI: 10.1016/j.chroma.2009.04.078

Penney, L., C. Bergeron and A. Wijewickreme, 2005. Simultaneous determination of residues of dipyrone and its major metabolites in milk, bovine muscle and porcine muscle by liquid chromatography/mass spectrometry. J. AOAC. Int., 88: 496-504. PMID: 15859077

Russell, W.M.S and R.L. Burch, 1959. The Principles of Humane Experimental Technique. 1st Edn., Methuen, The University of Michigan, Springfield, UK, pp: 238.

Smith, G.W., J.L. Davis, L.A. Tell, A.I. Webb and J.E. Riviere, 2008. Extralabel use of nonsteroidal anti-inflammatory drugs in cattle. J. Am. Vet. Med. Assoc., 232: 697-701. DOI: 10.2460/javma.232.5.697

Stolker, A.A.M., P. Rutgers, E. Oosterink, J.J.P. Lasaroms and R.J.B. Peters et al., 2008. Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. Anal. Bioanal. Chem., 391: 2309-2322. DOI: 10.1007/s00216-008-2168-8

Takeda, A., H. Tanaka, T. Shinorhara and I. Ohtake, 2001. Systematic analysis of acid, neutral and basic drugs in horse plasma by combination of solid-phase extraction, non-aqueous partitioning and gas chromatography-mass spectrometry. J. Chromatogr. B: Biomd. Sci. Appl., 758: 235-248. DOI: 10.1016/S0378-4347(01)00189-X

Van Hoof, N., K. De Wasch, S. Poelmans, H. Noppe and H. De Brabander, 2004. Multi-residue liquid chromatography/tandem mass spectrometry method for the detection of non-steroidal anti-inflammatory drugs in bovine muscle: Optimisation of ion trap parameters. Rapid Commun. Mass Spectrom., 18: 2823-2829. DOI: 10.1002/rcm.1683

Vinci, F., S. Fabbrocino, M. Fiori, L. Serpe and P. Gallo, 2006. Determination of fourteen non-steroidal anti-inflammatory drugs in animal serum and plasma by liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom., 20: 3412-3420. DOI: 10.1002/rcm.2748

Woodward, K., 2012. Toxicological Effects of Veterinary Medicinal Products in Humans. 1st Edn., Royal Society of Chemistry, UK., ISBN-10: 1849736847, pp: 446.